Abbott Reports First-Quarter 2025 Results and Reaffirms Full-Year Guidance

Rhea-AI Summary

Abbott (NYSE: ABT) reported strong first-quarter 2025 results with reported sales growth of 4.0% and organic sales growth of 6.9%. First-quarter GAAP diluted EPS reached $0.76, while adjusted diluted EPS was $1.09, showing double-digit growth year-over-year.

Key financial metrics include a reported gross margin of 52.8% and adjusted gross margin of 57.1%, reflecting a 140 basis point increase. The company's operating margin stood at 16.3%, with adjusted operating margin at 21.0%, up 130 basis points.

Notable developments include: CE Mark approval for Volt™ PFA System, initiation of the TECTONIC trial for Coronary IVL System, and positive two-year data from TRILUMINATE™ trial for TriClip™ device. Abbott reaffirmed its full-year 2025 guidance, projecting organic sales growth of 7.5-8.5% and adjusted diluted EPS of $5.05-$5.25.

Positive

• Double-digit organic growth in Medical Devices segment at 12.6%
• Diabetes Care CGM sales reached $1.7B with 21.6% organic growth
• Adjusted gross margin increased 140 basis points to 57.1%
• Adjusted operating margin improved 130 basis points to 21.0%
• 53 consecutive years of dividend increases maintained

Negative

• Diagnostics sales declined 7.2% on reported basis
• COVID-19 testing sales dropped to $84M from $204M year-over-year
• Core Laboratory Diagnostics impacted by volume-based procurement in China
• International Pediatric Nutrition sales decreased 8.4%

Insights

Financial Analyst

Abbott's Q1 2025 results demonstrate robust financial performance with 4.0% reported sales growth and 6.9% organic growth. When excluding COVID-19 testing sales, organic growth reached an impressive 8.3%. The company achieved double-digit EPS growth with adjusted EPS of $1.09, reflecting strong operational execution.

The results highlight Abbott's success in margin expansion, with adjusted gross margin increasing 140 basis points to 57.1% and adjusted operating margin rising 130 basis points to 21.0%. This margin improvement demonstrates effective cost management and the benefit of a favorable product mix shift.

Medical Devices emerged as the standout segment with 12.6% organic growth, led by the Diabetes Care division where continuous glucose monitors (primarily FreeStyle Libre) generated $1.7 billion in sales with 21.6% organic growth. Structural Heart products showed strong momentum with 14.7% organic growth.

The Nutrition business recovered nicely with 6.8% organic growth, with particular strength in Adult Nutrition (8.7% organic growth). Established Pharmaceuticals delivered 7.8% organic growth, with Key Emerging Markets up 9.3% organically.

The only underperforming segment was Diagnostics, with an organic decline of 4.9%, though this was largely due to the expected decrease in COVID-19 testing. Excluding COVID testing, this segment actually grew 0.5% organically.

Management's reaffirmation of full-year 2025 guidance (7.5-8.5% organic sales growth, $5.05-$5.25 adjusted EPS) signals confidence in continued momentum. Abbott's investment in manufacturing and R&D ($0.5 billion) and significant product milestones (CE Mark for Volt PFA System, TECTONIC trial initiation) position the company well for sustained long-term growth.

Medical Technology Expert

Abbott's Q1 results showcase its innovation pipeline's strength through several key product developments. The earlier-than-expected CE Mark for the Volt™ PFA System for atrial fibrillation treatment represents a significant advancement in Abbott's electrophysiology portfolio. Pulsed field ablation technology offers potential advantages over traditional thermal ablation methods, addressing a $8+ billion global market with growing prevalence of AFib.

The initiation of the TECTONIC pivotal trial for Coronary Intravascular Lithotripsy signals Abbott's expansion into calcified coronary artery disease treatment, complementing its established stent business. This technology addresses a challenging patient population with complex coronary lesions that are difficult to treat with conventional approaches.

The new two-year data from the TRILUMINATE™ trial for the TriClip™ device demonstrates sustained clinical benefits with significant reductions in heart failure hospitalizations. This evidence strengthens TriClip's clinical utility and commercial positioning for treating tricuspid regurgitation, a condition that affects approximately 1.6 million Americans.

In diabetes technology, FreeStyle Libre continues its remarkable growth trajectory (21.6% organic growth), validating Abbott's strategic focus on glucose monitoring innovation. With $1.7 billion in CGM sales this quarter alone, Abbott has established itself as a leader in diabetes technology.

The $0.5 billion investment in new manufacturing and R&D facilities in Illinois and Texas demonstrates Abbott's commitment to innovation infrastructure. These facilities will likely accelerate product development cycles and enhance manufacturing capabilities for key growth products.

This quarter's results reveal Abbott's successful execution of its innovation strategy, with strong performance across multiple therapeutic areas and significant advancements in its product pipeline that address substantial unmet clinical needs.

• First-quarter GAAP diluted EPS of $0.76; adjusted diluted EPS of $1.09
• First-quarter reported sales growth of 4.0 percent; organic sales growth of 6.9 percent or 8.3 percent when excluding COVID-19 testing-related sales¹
• Reported gross margin of 52.8 percent of sales; adjusted gross margin of 57.1 percent, which reflects a 140 basis point increase
• Reported operating margin of 16.3 percent of sales; adjusted operating margin of 21.0 percent, which reflects a 130 basis point increase

ABBOTT PARK, Ill., April 16, 2025 /PRNewswire/ --  Abbott (NYSE: ABT) today announced financial results for the first quarter ended March 31, 2025.

• First-quarter sales increased 4.0 percent on a reported basis, 6.9 percent on an organic basis, or 8.3 percent when excluding COVID-19 testing-related sales.
• First-quarter GAAP diluted EPS of $0.76 and adjusted diluted EPS of $1.09, which excludes specified items and reflects double-digit growth compared to the prior year.
• Abbott reaffirms all previously provided full-year 2025 financial guidance.
• In March, Abbott obtained CE Mark for its Volt^™ PFA System to treat patients battling atrial fibrillation (AFib). With the earlier-than-expected CE Mark, Abbott has begun commercial PFA cases in the EU with physicians who have already gained experience with the Volt PFA System through participation in Abbott's PFA clinical studies. The company will further expand the use of Volt in EU markets throughout the second half of the year.
• In March, Abbott announced the initiation of its U.S. pivotal trial, TECTONIC, to evaluate its investigational Coronary Intravascular Lithotripsy (IVL) System in treating severe calcification in coronary arteries prior to implanting a stent.
• In March, Abbott presented new two-year data from its TRILUMINATE^™ pivotal trial that showed Abbott's TriClip^™ device significantly reduced the rate of heart failure-related hospitalizations, while continuing to provide a sustained reduction of tricuspid regurgitation and significant improvements in quality of life.
• Abbott's two new manufacturing and R&D investments in Illinois and Texas, totaling $0.5 billion, are projected to go live by the end of 2025.

"Once again, Abbott's diversified business model delivered top-tier sales and EPS growth," said Robert B. Ford, chairman and chief executive officer, Abbott. "It is this diversification and execution that allows Abbott to navigate through periods of uncertainty and continually deliver sustainable growth."

FIRST-QUARTER BUSINESS OVERVIEW
Management believes that measuring sales growth rates on an organic basis, which excludes the impact of foreign exchange and the impact of discontinuing the ZonePerfect^® product line in the Nutrition business, is an appropriate way for investors to best understand the core underlying performance of the business.

Note: In order to compute results excluding the impact of exchange rates, current year U.S. dollar sales are multiplied or divided, as appropriate, by the current year average foreign exchange rates and then those amounts are multiplied or divided, as appropriate, by the prior year average foreign exchange rates.  

First Quarter 2025 Results (1Q25)
Sales 1Q25 ($ in millions)	Total Company		Nutrition		Diagnostics		Established Pharmaceuticals		Medical Devices
U.S.	4,168		955		871		—		2,339
International	6,190		1,191		1,183		1,260		2,556
Total reported	10,358		2,146		2,054		1,260		4,895
% Change vs. 1Q24
U.S.	8.4		8.8		(6.4)		n/a		15.0
International	1.2		0.1		(7.8)		2.7		5.7
Total reported	4.0		3.8		(7.2)		2.7		9.9
Impact of foreign exchange	(2.8)		(2.4)		(2.3)		(5.1)		(2.7)
Impact of business exit*	(0.1)		(0.6)		—		—		—
Organic	6.9		6.8		(4.9)		7.8		12.6
U.S.	8.8		10.4		(6.4)		n/a		15.0
International	5.7		4.2		(3.8)		7.8		10.5

 

Refer to table titled "Non-GAAP Revenue Reconciliation" for a reconciliation of adjusted historical revenue to reported revenue.

*Quarter to date March 31, 2025, reflects the impact of discontinuing the ZonePerfect® product line in the Nutrition business in March 2024.

Total company sales increased 4.0 percent on a reported basis, 6.9 percent on an organic basis, or 8.3 percent when excluding COVID-19 testing-related sales¹. 

Nutrition
First Quarter 2025 Results (1Q25)
Sales 1Q25 ($ in millions)	Total		Pediatric		Adult
U.S.	955		588		367
International	1,191		453		738
Total reported	2,146		1,041		1,105
% Change vs. 1Q24
U.S.	8.8		14.2		1.1
International	0.1		(8.4)		6.1
Total reported	3.8		3.2		4.4
Impact of foreign exchange	(2.4)		(1.7)		(2.9)
Impact of business exit*	(0.6)		—		(1.4)
Organic	6.8		4.9		8.7
U.S.	10.4		14.2		4.8
International	4.2		(4.8)		10.6

*Reflects the impact of discontinuing the ZonePerfect® product line. This action was initiated in March 2024.

Worldwide Nutrition sales increased 3.8 percent on a reported basis and 6.8 percent on an organic basis in the first quarter.

In Pediatric Nutrition, global sales increased 3.2 percent on a reported basis and 4.9 percent on an organic basis. Sales growth in the U.S. was driven by growth across Abbott's comprehensive portfolio of products designed to meet the unique nutrition needs of infants and children.

In Adult Nutrition, global sales increased 4.4 percent on a reported basis and 8.7 percent on an organic basis, which was led by strong growth of Ensure^®, Abbott's market-leading complete and balanced nutrition brand, and Glucerna^®, Abbott's market-leading brand of products designed to meet the nutritional requirements for people with diabetes. 

Diagnostics
First Quarter 2025 Results (1Q25)
Sales 1Q25 ($ in millions)	Total		Core Laboratory		Molecular		Point of Care		Rapid Diagnostics
U.S.	871		332		40		100		399
International	1,183		845		82		42		214
Total reported	2,054		1,177		122		142		613
% Change vs. 1Q24
U.S.	(6.4)		7.1		(4.4)		1.5		(16.9)
International	(7.8)		(5.6)		(6.7)		4.4		(17.9)
Total reported	(7.2)		(2.3)		(5.9)		2.4		(17.3)
Impact of foreign exchange	(2.3)		(3.2)		(2.4)		(0.8)		(1.2)
Organic	(4.9)		0.9		(3.5)		3.2		(16.1)
U.S.	(6.4)		7.1		(4.4)		1.5		(16.9)
International	(3.8)		(1.3)		(3.1)		7.3		(14.6)

 

Global Diagnostics sales decreased 7.2 percent on a reported basis, decreased 4.9 percent on an organic basis, or increased 0.5 percent when excluding COVID-19 testing-related sales¹.

Diagnostics sales growth was impacted by the year-over-year decline in COVID-19 testing-related sales and volume-based procurement programs in China.

COVID-19 testing-related sales were $84 million in the quarter, compared to $204 million in the first quarter of the prior year.

Global Core Laboratory Diagnostics sales decreased 2.3 percent on a reported basis and increased 0.9 percent on an organic basis. Growth in the quarter was impacted by volume-based procurement programs in China. 

Established Pharmaceuticals
First Quarter 2025 Results (1Q25)
Sales 1Q25 ($ in millions)	Total		Key Emerging Markets		Other
U.S.	—		—		—
International	1,260		965		295
Total reported	1,260		965		295
% Change vs. 1Q24
U.S.	n/a		n/a		n/a
International	2.7		4.0		(1.2)
Total reported	2.7		4.0		(1.2)
Impact of foreign exchange	(5.1)		(5.3)		(4.3)
Organic	7.8		9.3		3.1
U.S.	n/a		n/a		n/a
International	7.8		9.3		3.1

 

Established Pharmaceuticals sales increased 2.7 percent on a reported basis and 7.8 percent on an organic basis in the first quarter.

Key Emerging Markets include several emerging countries that represent the most attractive long-term growth opportunities for Abbott's branded generics product portfolio. Sales in these geographies increased 4.0 percent on a reported basis and 9.3 percent on an organic basis, led by double-digit growth in several countries across Asia, Latin America and the Middle East. 

Medical Devices
First Quarter 2025 Results (1Q25)
Sales 1Q25 ($ in millions)	Total		Rhythm Management		Electro- physiology		Heart Failure		Vascular		Structural Heart		Neuro- modulation		Diabetes Care
U.S.	2,339		304		299		262		268		282		176		748
International	2,556		281		330		77		442		295		52		1,079
Total reported	4,895		585		629		339		710		577		228		1,827
% Change vs. 1Q24
U.S.	15.0		12.3		11.1		10.6		5.5		20.9		(2.8)		27.1
International	5.7		(3.7)		4.0		14.3		1.6		4.6		16.3		10.1
Total reported	9.9		4.0		7.3		11.4		3.0		11.9		1.0		16.5
Impact of foreign exchange	(2.7)		(2.1)		(2.6)		(1.0)		(2.7)		(2.8)		(1.2)		(3.3)
Organic	12.6		6.1		9.9		12.4		5.7		14.7		2.2		19.8
U.S.	15.0		12.3		11.1		10.6		5.5		20.9		(2.8)		27.1
International	10.5		0.3		8.8		19.1		5.8		9.6		22.7		15.4

 

Worldwide Medical Devices sales increased 9.9 percent on a reported basis and 12.6 percent on an organic basis in the first quarter.

Sales growth in the quarter was led by Diabetes Care, Structural Heart, Heart Failure and Electrophysiology.

Several products contributed to the strong performance, including FreeStyle Libre^®, Navitor^®, TriClip^®, Amplatzer^® Amulet^®, and AVEIR^®.

In Diabetes Care, sales of continuous glucose monitors were $1.7 billion and grew 18.3 percent on a reported basis and 21.6 percent on an organic basis.

ABBOTT'S FINANCIAL GUIDANCE
Abbott projects full-year 2025 organic sales growth to be in the range of 7.5% to 8.5%.

Abbott projects full-year 2025 adjusted operating margin to be 23.5% to 24.0% of sales.

Abbott projects full-year 2025 adjusted diluted earnings per share of $5.05 to $5.25 and second-quarter 2025 adjusted diluted earnings per share of $1.23 to $1.27.

Abbott has not provided the related GAAP financial measures on a forward-looking basis for these forward-looking non-GAAP financial measures because the company is unable to predict with reasonable certainty and without unreasonable effort the timing and impact of certain items such as restructuring and cost reduction initiatives, charges for intangible asset impairments, acquisition-related expenses, and foreign exchange, which could significantly impact Abbott's results in accordance with GAAP.

ABBOTT DECLARES 405^th CONSECUTIVE QUARTERLY DIVIDEND
On Feb. 21, 2025, the board of directors of Abbott declared the company's quarterly dividend of $0.59 per share. Abbott's cash dividend is payable May 15, 2025, to shareholders of record at the close of business on April 15, 2025.

Abbott has increased its dividend payout for 53 consecutive years and is a member of the S&P 500 Dividend Aristocrats Index, which tracks companies that have annually increased their dividend for at least 25 consecutive years.

About Abbott:
Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 114,000 colleagues serve people in more than 160 countries.

Connect with us at www.abbott.com and on LinkedIn, Facebook, Instagram, X and YouTube. 

Abbott will live-webcast its first-quarter earnings conference call through its Investor Relations website at www.abbottinvestor.com at 8 a.m. Central time today. An archived edition of the webcast will be available later in the day.

— Private Securities Litigation Reform Act of 1995 —
A Caution Concerning Forward-Looking Statements

Some statements in this news release may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbott's operations are discussed in Item 1A, "Risk Factors" in our Annual Report on Form 10-K for the year ended Dec. 31, 2024, and are incorporated herein by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.

1.

In the first quarter of 2025, total worldwide sales were $10.358 billion, total Diagnostics sales were $2.054 billion and COVID-19 testing-related sales were $84 million. In the first quarter of 2024, total worldwide sales were $9.964 billion, total Diagnostics sales were $2.214 billion and COVID-19 testing-related sales were $204 million. In the first quarter of 2025, the impact of COVID-19 testing-related sales on Abbott and total Diagnostics was a decrease of 1.4 percent and 5.4 percent, respectively. Organic sales, excluding COVID-19 testing-related sales, increased 8.3 percent for Abbott and 0.5 percent for total Diagnostics.

 

Abbott Laboratories and Subsidiaries Condensed Consolidated Statement of Earnings First Quarter Ended March 31, 2025 and 2024 (in millions, except per share data) (unaudited)
	1Q25		1Q24		% Change
Net Sales	$10,358		$9,964		4.0
Cost of products sold, excluding amortization expense	4,468		4,463		0.1
Amortization of intangible assets	420		472		(11.0)
Research and development	716		684		4.6
Selling, general, and administrative	3,061		2,959		3.5
Total Operating Cost and Expenses	8,665		8,578		1.0
Operating Earnings	1,693		1,386		22.1
Interest expense, net	49		61		(18.6)
Net foreign exchange (gain) loss	(7)		—		n/m
Other (income) expense, net	(127)		(111)		14.9
Earnings before taxes	1,778		1,436		23.8
Taxes on earnings	453		211		n/m	1)
Net Earnings	$1,325		$1,225		8.2
Net Earnings excluding Specified Items, as described below	$1,919		$1,729		10.9	2)
Diluted Earnings per Common Share	$0.76		$0.70		8.6
Diluted Earnings per Common Share, excluding Specified Items, as described below	$1.09		$0.98		11.2	2)
Average Number of Common Shares Outstanding Plus Dilutive Common Stock Options	1,747		1,750

 

NOTES:
See table titled "Non-GAAP Reconciliation of Financial Information" for an explanation of certain non-GAAP financial information.
n/m = Percent change is not meaningful.
See footnotes on the following section.
1)	2025 Taxes on Earnings includes approximately $200 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.
	2024 Taxes on Earnings includes the recognition of approximately $10 million of net tax expense as a result of the resolution of various tax positions related to prior years.
2)	2025 Net Earnings and Diluted Earnings per Common Share, excluding Specified Items, excludes net after-tax charges of $594 million, or $0.33 per share, for intangible amortization, charges related to investment impairments, charges related to restructuring and cost reduction initiatives, expenses associated with acquisitions, and other net expenses.
	2024 Net Earnings and Diluted Earnings per Common Share, excluding Specified Items, excludes net after-tax charges of $504 million, or $0.28 per share, for intangible amortization, charges related to restructuring and cost reduction initiatives, expenses associated with acquisitions and other net expenses.

 

Abbott Laboratories and Subsidiaries Non-GAAP Reconciliation of Financial Information First Quarter Ended March 31, 2025 and 2024 (in millions, except per share data) (unaudited)
	1Q25
	As Reported (GAAP)		Specified Items		As Adjusted
Intangible Amortization	$            420		$          (420)		$              —
Gross Margin	5,470		448		5,918
R&D	716		(27)		689
SG&A	3,061		(10)		3,051
Other (income) expense, net	(127)		(35)		(162)
Earnings before taxes	1,778		520		2,298
Taxes on Earnings	453		(74)		379
Net Earnings	1,325		594		1,919
Diluted Earnings per Share	$           0.76		$           0.33		$           1.09

 

Specified items reflect intangible amortization expense of $420 million and other net expenses of $100 million associated with restructuring actions, costs associated with acquisitions, investment impairment charges and other net expenses. See table titled "Details of Specified Items" for additional details regarding specified items.

	1Q24
	As Reported (GAAP)		Specified Items		As Adjusted
Intangible Amortization	$            472		$          (472)		$              —
Gross Margin	5,029		518		5,547
R&D	684		(21)		663
SG&A	2,959		(34)		2,925
Other (income) expense, net	(111)		(26)		(137)
Earnings before taxes	1,436		599		2,035
Taxes on Earnings	211		95		306
Net Earnings	1,225		504		1,729
Diluted Earnings per Share	$           0.70		$           0.28		$           0.98

 

Specified items reflect intangible amortization expense of $472 million and other net expenses of $127 million associated with restructuring actions, costs associated with acquisitions, investment impairment charges and other net expenses. See table titled "Details of Specified Items" for additional details regarding specified items.

A reconciliation of the first-quarter tax rates for 2025 and 2024 is shown below: 

	1Q25
($ in millions)	Pre-Tax Income		Taxes on Earnings		Tax Rate
As reported (GAAP)	$         1,778		$            453		25.5 %	1)
Specified items	520		(74)
Excluding specified items	$         2,298		$            379		16.5 %
	1Q24
($ in millions)	Pre-Tax Income		Taxes on Earnings		Tax Rate
As reported (GAAP)	$         1,436		$            211		14.7 %	2)
Specified items	599		95
Excluding specified items	$         2,035		$            306		15.0 %

1)	2025 Taxes on Earnings includes approximately $200 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.
2)	2024 Taxes on Earnings includes the recognition of approximately $10 million of net tax expense as a result of the resolution of various tax positions related to prior years.

 

Abbott Laboratories and Subsidiaries Non-GAAP Revenue Reconciliation First Quarter Ended March 31, 2025 and 2024 ($ in millions) (unaudited)
		1Q25		1Q24				% Change vs. 1Q24
										Non-GAAP
		Abbott Reported		Abbott Reported	Impact from business exit (a)	Adjusted Revenue		Reported		Adjusted	Organic
Total Company		10,358		9,964	(13)	9,951		4.0		4.1	6.9
U.S.		4,168		3,846	(13)	3,833		8.4		8.8	8.8
Intl		6,190		6,118	—	6,118		1.2		1.2	5.7
Total Nutrition		2,146		2,068	(13)	2,055		3.8		4.4	6.8
U.S.		955		878	(13)	865		8.8		10.4	10.4
Intl		1,191		1,190	—	1,190		0.1		0.1	4.2
Adult Nutrition		1,105		1,059	(13)	1,046		4.4		5.8	8.7
U.S.		367		364	(13)	351		1.1		4.8	4.8
Intl		738		695	—	695		6.1		6.1	10.6

(a)	Reflects the impact of discontinuing the ZonePerfect® product line in the Nutrition business. This action was initiated in March 2024.

 

Abbott Laboratories and Subsidiaries Details of Specified Items First Quarter Ended March 31, 2025 (in millions, except per share data) (unaudited)
	Acquisition or Divestiture- related (a)		Restructuring and Cost Reduction Initiatives (b)		Intangible Amortization		Other (c)		Total Specifieds
Gross Margin	$                  —		$                  26		$                420		$                    2		$                448
R&D	(1)		(16)		—		(10)		(27)
SG&A	(3)		(7)		—		—		(10)
Other (income) expense, net	(24)		—		—		(11)		(35)
Earnings before taxes	$                  28		$                  49		$                420		$                  23		520
Taxes on Earnings (d)									(74)
Net Earnings									$                594
Diluted Earnings per Share									$               0.33

The table above provides additional details regarding the specified items described on table titled "Non-GAAP Reconciliation of Financial Information."
a)	Acquisition-related expenses include integration costs, which represent incremental costs directly related to integrating acquired businesses as well as a fair value adjustment to contingent consideration related to a business acquisition.
b)	Restructuring and cost reduction initiative expenses include severance, outplacement and other direct costs associated with specific restructuring plans and cost reduction initiatives.
c)	Other includes incremental costs to comply with the European Union's Medical Device Regulations (MDR) and In Vitro Diagnostics Medical Device Regulations (IVDR) requirements for previously approved products and investment impairment charges.
d)	Reflects the net tax benefit associated with the specified items. 2025 Taxes on Earnings includes approximately $200 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.

 

Abbott Laboratories and Subsidiaries Details of Specified Items First Quarter Ended March 31, 2024 (in millions, except per share data) (unaudited)
	Acquisition or Divestiture- related (a)		Restructuring and Cost Reduction Initiatives (b)		Intangible Amortization		Other (c)		Total Specifieds
Gross Margin	$                    1		$                  42		$                472		$                    3		$                518
R&D	(3)		(2)		—		(16)		(21)
SG&A	(14)		(9)		—		(11)		(34)
Other (income) expense, net	12		—		—		(38)		(26)
Earnings before taxes	$                    6		$                  53		$                472		$                  68		599
Taxes on Earnings (d)									95
Net Earnings									$                504
Diluted Earnings per Share									$               0.28

The table above provides additional details regarding the specified items described on table titled "Non-GAAP Reconciliation of Financial Information."
a)	Acquisition-related expenses include integration costs, which represent incremental costs directly related to integrating acquired businesses, as well as other costs related to business acquisitions.
b)	Restructuring and cost reduction initiative expenses include severance, outplacement and other direct costs associated with specific restructuring plans and cost reduction initiatives.
c)	Other includes various investment impairment charges and incremental costs to comply with the European Union's Medical Device Regulations (MDR) and In Vitro Diagnostics Medical Device Regulations (IVDR) requirements for previously approved products.
d)	Reflects the net tax benefit associated with the specified items.

 

View original content:https://www.prnewswire.com/news-releases/abbott-reports-first-quarter-2025-results-and-reaffirms-full-year-guidance-302430212.html

SOURCE Abbott

FAQ

What is Abbott's projected organic sales growth for 2025?

Abbott projects full-year 2025 organic sales growth to be in the range of 7.5% to 8.5%.

How much did Abbott's Medical Devices segment grow in Q1 2025?

Abbott's Medical Devices sales increased 9.9% on a reported basis and 12.6% on an organic basis in Q1 2025.

What is Abbott's Q1 2025 dividend payment?

Abbott declared a quarterly dividend of $0.59 per share, payable May 15, 2025.

What was Abbott's Q1 2025 adjusted EPS and guidance?

Abbott reported Q1 2025 adjusted EPS of $1.09 and projects full-year 2025 adjusted EPS of $5.05 to $5.25.

How did Abbott's Diabetes Care segment perform in Q1 2025?

Diabetes Care continuous glucose monitors generated $1.7B in sales, growing 18.3% reported and 21.6% organic.